OmicXHealth
Pre-seed startup developing non-invasive early cancer detection tests using AI/ML analysis of circulating cell-free DNA (cfDNA) methylation. The team builds bioinformatics pipelines and machine learning models trained on bisulfite-sequenced datasets and limited clinical samples, and is progressing toward CLIA Laboratory Developed Test (LDT) validation and clinical pilot studies. Recent milestones include external sequencing collaborations, a patent filing for a "sequence once, analyze many times" software-driven approach, conference presentations, and selection to an accelerator program.
Industries
N/A
Nr. of Employees
small (1-50)
Products
AI/ML-driven cfDNA methylation analysis platform
A modular software platform that analyzes genome-scale methylation data from cfDNA to detect cancer signals; designed to support multiple assay types via model ensembles and meta-classification.
AI/ML-driven cfDNA methylation analysis platform
A modular software platform that analyzes genome-scale methylation data from cfDNA to detect cancer signals; designed to support multiple assay types via model ensembles and meta-classification.
Services
Sequencing of clinical/biobank samples and calibration of computational models to a locked wet-lab protocol in partnership with sequencing laboratories.
Sequencing of clinical/biobank samples and calibration of computational models to a locked wet-lab protocol in partnership with sequencing laboratories.
Expertise Areas
- Liquid biopsy diagnostics
- cfDNA methylation profiling
- Bioinformatics pipeline development
- Machine learning for genomics
Key Technologies
- Bisulfite sequencing
- cfDNA methylation profiling
- Whole-genome methylation sequencing
- Random Forest
News & Updates
Accepted into the Bronco Ventures Accelerator program at Santa Clara University to support go-to-market strategy and company growth.
Sequencing of a small set of 12 biobank blood samples by an external provider and analysis using the company's methylation models, with top models correctly identifying 10–11 of 12 cases.
Participation and presentations at industry conferences in 2025 highlighting AI-driven approaches to diagnostics.
Summary of structured interviews with hepatologists, gastroenterologists, oncologists and clinical researchers informing clinical strategy, use cases, and evidence thresholds.
Blog post describing initial sequencing and model evaluation on 12 biobank samples and confirmation of assay-software alignment.
Overview of technical approach, use of public bisulfite datasets, preprocessing pipeline, and platform architecture enabling cross-assay generalization.
Accepted into the Bronco Ventures Accelerator program at Santa Clara University to support go-to-market strategy and company growth.
Sequencing of a small set of 12 biobank blood samples by an external provider and analysis using the company's methylation models, with top models correctly identifying 10–11 of 12 cases.
Participation and presentations at industry conferences in 2025 highlighting AI-driven approaches to diagnostics.
Summary of structured interviews with hepatologists, gastroenterologists, oncologists and clinical researchers informing clinical strategy, use cases, and evidence thresholds.
Blog post describing initial sequencing and model evaluation on 12 biobank samples and confirmation of assay-software alignment.
Overview of technical approach, use of public bisulfite datasets, preprocessing pipeline, and platform architecture enabling cross-assay generalization.